Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition.
Hepatocellular carcinoma (HCC) is the fifth common malignancy worldwide and the third leading cause of cancer-related death. Targeted therapies for HCC are being extensively developed with the limited success of sorafinib. In the present study, we investigated the potential antitumor activity of zar...
Saved in:
| Main Authors: | Liping Sun, Haitian Quan, Chengying Xie, Lei Wang, Youhong Hu, Liguang Lou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0090627&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of phosphodiesterase inhibitors in the bladder
by: Bilal Chughtai, et al.
Published: (2015-01-01) -
Discovery of highly potent phosphodiesterase-1 inhibitors by a combined-structure free energy perturbation approach
by: Zhe Li, et al.
Published: (2024-12-01) -
Phosphodiesterase-5 inhibitors: Raynaud's and beyond
by: Sanat Phatak, et al.
Published: (2017-01-01) -
Potent β-lactam-based tyrosyl-DNA phosphodiesterase 1 inhibitors identified by a virtual screen
by: Xue Zhi Zhao, et al.
Published: (2025-07-01) -
Phosphodiesterase type 5 inhibitors and erectile dysfunction
by: Catherine Whittaker
Published: (2010-06-01)